Last reviewed · How we verify
Propolis
Propolis, developed by Cairo University, is a marketed product with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but the patent protection provides a competitive advantage until 2028. The primary risk is the lack of detailed revenue and clinical trial data, which may limit investor confidence and market expansion.
At a glance
| Generic name | Propolis |
|---|---|
| Also known as | natural irrigant, sulawesian propolis, propolis bee resin, Bee glue, BioPropolis |
| Sponsor | Cairo University |
| Drug class | Acetylcholine Release Inhibitor [EPC] |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Effect of Oral Use of Lyophilised Royal Jelly on Cognitive Functions and Immune System in Elderly Individuals (NA)
- The Effect of Oral Care With Propolis in COPD Patients (NA)
- Assessing the Impact of Herbal Supplement on Fatigue and Disease Activity in SLE: Results From an 8-Week Randomized Trial (NA)
- Effects of Propolis Flavonoids on TLR4 Signaling and Inflammation in Human PDLSCs In Vitro
- 'Propolis Versus Chlorhexidine Gluconate on Wound Healing After Third Molar Surgery: a Randomized Controlled Trial' (NA)
- Royal Jelly Supplementation in Unexplained Male Infertility (NA)
- Effect of Toothpastes on Oral Malodor (NA)
- Comparison Between Topical N-acetyl Cysteine (NAC) in Cold Cream Versus Cold Cream in Mild and Moderate Atopic Dermatitis: Clinical and Bacteriological Evaluation. A Randomized Control Trial. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |